Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

Fig. 3

Unadjusted Kaplan–Meier event curves for in-hospital mortality from commencment of invasive mechanical ventilation to 90 days. A Before propensity score matching, 90-day ICU Kaplan-Meier curves differed between patients undergoing up to three-day NMBA therapy, within 48 hours from commencement of IMV, in comparison with those who did not (N = 1953, p < 0.001). B After propensity score matching, no difference in survival between patients undergoing NMBA therapy in comparison with those who did not was found (N = 420, due to equally sized cohorts post propensity score matching, P = 0.537). NMBA neuromuscular blocking agent, ICU intensive care unit

Back to article page